Drug Allergy Records: Separate Unknown from None Known
Record uncertain allergy histories with source-preserving examples, dated assessments and checks across prescribing, referral and export.
An NSAID review should distinguish a suspected drug-allergic reaction, other adverse effects, relevant conditions and interacting medicines. “Gastritis”, “asthma” and “ibuprofen allergy” are not interchangeable entries. Preserve the actual event and its uncertainty, then let the clinician assess the proposed product. Correcting an inaccurate allergy label must not erase a separate reason the medicine may be unsuitable.
Indian doctors and clinic teams reviewing diclofenac, ibuprofen and other NSAID histories before issuing or repeating a prescription.
A warning can concern an earlier suspected allergic reaction, a non-allergic adverse effect, an underlying condition or another medicine. These categories require different evidence. A single red badge labelled “sensitive” gives the prescriber little help in deciding what the patient experienced or what needs review today.
Start with the patient’s words and the exact product where known. In an Indian OPD, the patient may remember a painkiller brand or show a strip containing more than one ingredient. Verify the components rather than assuming the event came from the best-known ingredient. Record an uncertain name as uncertain.
The clinician then decides how to represent the event and what it means for the proposed treatment. A well-organised record can hold more than one concern at once. There is no need to choose between an allergy field and a gastrointestinal history when both contain clinically relevant but different information.
Ask what happened, how soon it followed the medicine, whether it recurred and what care was needed. “Stomach discomfort after a pain tablet” and “breathing difficulty after a named medicine requiring emergency care” must not be compressed into the same generic reaction. Keep the source and reliability of the history visible.
NICE notes that isolated gastrointestinal symptoms are less suggestive of drug allergy and treats suspected NSAID reactions separately from other histories. This is UK guidance, used here to explain why symptoms need accurate classification. It does not mean gastrointestinal harm is unimportant or that a medicine becomes suitable once the allergy label changes.
If an acute severe reaction is occurring, clinical assessment and urgent care take priority over completing the electronic record. After the immediate response, document the chronology and treatment with the responsible clinician. A retrospectively completed form should show when the event occurred and when the account was entered.
Source: NICE CG183: Drug allergy—NSAID history and referral recommendations
Record whether respiratory symptoms followed a particular NSAID, the timing, treatment required and any relevant specialist assessment. A general asthma diagnosis and a documented medicine-triggered respiratory reaction are different facts. Do not replace one with the other because the interface has room for only a single checkbox.
NICE specifically highlights asthma with nasal polyps when assessing possible NSAID sensitivity. That is a reason to obtain a careful history and appropriate review, not a licence for reception to select an alternative analgesic. The exact patient context and prior reactions remain important.
A history of later tolerated treatment can be useful, but it needs an exact medicine, time and source. An unnamed painkiller taken years ago cannot reliably clear every current product. Preserve any specialist advice about particular medicines without expanding it beyond the conclusion actually given.
Source: NICE CG183: Drug allergy—NSAID history and referral recommendations
This original matrix organises the review. It does not rank analgesics or specify which drug a patient should receive. Its purpose is to prevent a coding correction in one category from making another unresolved concern disappear.
On a narrow screen, scroll the table horizontally to read all columns.
| Concern | Evidence to preserve | Question for the clinician |
|---|---|---|
| Suspected allergic reaction | Product, symptoms, timing, treatment and certainty | What does the reaction imply for the proposed medicine and further assessment? |
| Gastrointestinal adverse effect or history | Actual event, diagnosis if established and relevant records | What risk remains even if this is not classified as allergy? |
| Respiratory context | Asthma history, nasal-polyposis context and any drug-linked event | Does this history require a different clinical assessment or specialist advice? |
| Kidney-function concern | Dated results, source and current clinical circumstances | Is the available evidence adequate for this prescribing decision? |
| Other current medicines | Verified ingredients and actual use, including non-prescription products | Are there overlapping or interacting treatments to resolve? |
| Combination product | Every component, strength and formulation | Which ingredients were present during the event or proposed order? |
| Uncertain or conflicting account | Both sources and their limits | Who will clarify the uncertainty before the next clinical action? |
Fictional patient N-26 attends a Jaipur OPD with two medicine strips and a phone photograph of an earlier pack. The old chart contains one entry: “painkiller allergy—gastritis”. During the conversation, the doctor identifies two separate episodes: stomach discomfort after one product in April and wheezing after a different product in September. The patient also has another pain medicine at home. Collapsing all of this into one allergy field would obscure both the sequence and the ingredients.
In this invented example, the April photograph shows product A containing ibuprofen and paracetamol; the September strip shows product B containing diclofenac; the current strip is product C containing paracetamol. These are three product identities and three distinct active ingredients. Paracetamol appears in two products. This establishes an ingredient overlap to investigate, not proof that the products were taken together, an excessive dose occurred or a particular ingredient caused either event.
Ask separately when each product was started, the last exposure before symptoms, the number of doses the patient recalls, what else was taken and what care followed. An approximate month should remain approximate. The April photograph establishes label content but not what was swallowed; the September strip identifies a supplied product but does not prove the timing of use. Keep those evidence limits beside the history rather than burying them in a general disclaimer.
The clinician cannot calculate a cumulative amount from names alone. Strength, quantity actually taken and exposure times would be needed, and the patient may not recall them reliably. “Unknown” is preferable to a default one-tablet schedule. If current symptoms or the reported exposure require prompt assessment, that response takes priority over finishing the reconstruction. The table is an original history exercise and supplies no recommended analgesic, dosing amount or substitution.
On a narrow screen, scroll the table horizontally to read all columns.
| Product evidence | Ingredients identified | Reported event or use | Limit that stays visible |
|---|---|---|---|
| A: photograph of April pack | Ibuprofen + paracetamol | Stomach discomfort during that treatment; exact dates and quantity not recalled | Photograph identifies the pack; neither ingredient is independently established as the cause |
| B: September strip brought to clinic | Diclofenac | Wheezing reported after use; patient recalls urgent care | Obtain available treatment record and chronology; severity and mechanism are not assigned from the strip |
| C: current strip brought to clinic | Paracetamol | Patient reports occasional use; recent amount and times remain unclear | Shares an ingredient with A; concurrent exposure and total amount are not established |
The doctor first revisits the old “gastritis” wording. In this case, the only available April account is stomach discomfort; no source establishing a diagnosis of gastritis is present. The corrected record should preserve that symptom and the clinician’s assessment without upgrading it into a diagnosis or erasing it. The September respiratory episode remains a different suspected medicine-related event, with its own evidence and review needs.
This matters when a clinic searches for an alternative by brand. Product A contains two ingredients and product B contains a different NSAID. A medicine catalogue can identify ingredients, but it cannot decide from these observations whether a reaction was selective, involved a broader pattern or had another explanation. Avoid presenting a new brand, a COX-2 medicine or a different route as automatically safe. The prescribing decision requires the relevant clinical assessment.
Use the following comparison to keep separate questions visible during handover. The respiratory history, gastrointestinal account, current medicine list and any kidney-function evidence do not need to fit into one status. The completed review should tell the next doctor which issue changed, which is unresolved and what action belongs to whom. Correcting “allergy” to another category is a documentation decision; selecting today’s treatment is a further clinical decision.
At a later visit, read the narrative before copying an old prescription set. The proposed medicine may differ from the one discussed here, and the patient may have obtained something else from a pharmacy. A record that says only “reviewed” is therefore insufficient. In a shared practice, retain the actual product, encounter and responsible clinician so the next prescriber can tell which review has been completed.
On a narrow screen, scroll the table horizontally to read all columns.
| Question | Conclusion supported by this case | Next clinical or documentation action |
|---|---|---|
| April gastrointestinal account | Stomach discomfort is reported; a diagnosis of gastritis is not established by the available source | Clinician records the symptom history and its assessment; preserve any continuing prescribing concern |
| September respiratory account | A separate wheezing episode after reported diclofenac use remains relevant | Clinician assesses the history and need for specialist input; staff seek the available urgent-care record |
| Current ingredient overlap | Paracetamol is present in A and C; dates do not establish simultaneous use | Clarify actual recent use before evaluating total exposure; no invented schedule or amount |
| Present treatment choice | Neither the corrected gastrointestinal entry nor the ingredient list selects a medicine | Responsible prescriber records the current decision, rationale and patient instructions |
For N-26, the receiving doctor needs a short explanation of why the chart changed. The filled note below deliberately retains an unresolved respiratory history and does not describe all pain medicines as suitable. It also avoids attributing the April event to both components of product A as though two independent reactions had been confirmed. A suspected product association and an ingredient-level conclusion are different levels of evidence.
Indian clinics can use the Pharmacovigilance Programme of India reporting route when a suspected adverse reaction is identified. IPC’s reporting page links healthcare-professional forms, monitoring centres and patient forms in Hindi and other Indian languages. These resources support reporting access; they do not replace the doctor’s treatment decision or certify a medicine safe for future use. Check the current official form and instructions rather than reusing an old screenshot.
If a report is prepared, distinguish preparation, submission and any acknowledgement in the clinic’s own record. Do not invent a monitoring-centre reference or record “reported” merely because a form was opened. Additional verified history can be linked to the existing case through the appropriate reporting process. The patient’s clinical record still needs the care provided, the agreed instructions and the review responsibility, regardless of a reporting acknowledgement.
Explain the revised record using the actual product identities. The patient should not leave believing that the stomach symptom was imaginary because it moved out of an allergy category, or that an unresolved breathing episode has been dismissed. Ask which packs they will show another doctor and which current instruction they understand. In this example, the patient can identify B as the product discussed in relation to wheezing, but the timing still needs clarification; a successful identification task does not resolve causation.
A practical acceptance check uses the history, consultation note and patient summary together. Confirm that all three show the separate September concern after the April category is edited. This is a better test of information preservation than counting fewer alerts. It does not validate a decision-support algorithm, establish that the patient followed the plan or measure a reduction in adverse reactions.
Source: Indian Pharmacopoeia Commission: PvPI adverse drug reaction reporting
If a clinician concludes that a historical entry was misclassified, move or clarify the information through an attributable correction. Preserve the symptom history, the assessment and any continuing precaution. Deleting the entire entry may make a future prescriber believe there was never a relevant problem.
Review affected saved favourites and prescription sets. A shortcut may keep proposing a product even after the clinician changes the patient’s plan. Conversely, a broad catalogue-level block can affect other patients unnecessarily if a patient-specific event was recorded in the wrong place.
Where a suspected adverse reaction should be reported, keep that reporting process distinct from the clinical record and treatment decision. A report can support medicine-safety surveillance without proving causation. The patient’s immediate care and future instructions need their own accountable follow-through.
Complete this outline with the responsible clinician. It is designed to expose the specific concern rather than produce an automatic drug choice. If the current product cannot be identified, retain that limitation instead of selecting a familiar NSAID as a placeholder.
Create a fictional patient with an uncertain painkiller-related breathing event, a separately documented gastrointestinal problem and a current combination product. Ask the demonstrator to show each source, identify the combination’s components and record the clinician’s decision. A single “no allergy” status should not hide the other concerns.
Next, clarify the historical allergy classification while retaining the gastrointestinal history. Inspect the consultation screen, medicine selection, patient summary and exported record. The important question is whether the remaining context stays available, not whether the warning count goes down.
For a small local audit, classify missing product identity, missing reaction chronology and missing decision ownership separately. One encounter can have more than one gap. Do not add overlapping categories together and describe the sum as a number of affected patients. Evaluate Bractis against these observable record needs without assuming it supplies validated NSAID decision support.
A patient’s old chart says “NSAID allergy—gastritis”. The clinician reviews the source and clarifies how the gastrointestinal event should be recorded. During the same visit, the patient reports a separate episode of wheezing after a pharmacy pain product whose ingredients are not yet known. The clinic retains the gastrointestinal history and records the uncertain respiratory event for assessment. Changing the first label does not clear the second event or authorise a new analgesic.
Use these prompts in your clinic’s own notes. Record the result, responsible person and next action for each item.
The clinician should classify the actual event from its evidence. Gastrointestinal symptoms and suspected drug allergy are different questions, but correcting the category must not erase a clinically relevant gastrointestinal history.
No. Record any medicine-linked respiratory event, relevant context, timing, treatment and specialist advice. A diagnosis alone does not describe the patient’s actual reaction history.
Verify every ingredient, strength and formulation from a reliable source. Similar names or incomplete recollections may hide a different product or overlapping treatment.
Not automatically. Other adverse effects, conditions, current medicines and the present indication may still require clinical assessment.
Capture the patient’s wording and available product information, preserve uncertainty and route the concern to the clinician. Reception should not select an alternative or reclassify the reaction independently.
No. Record the verified components, exposure and reaction chronology, including other medicines taken at the time. A product association does not independently establish each ingredient as the cause. Keep uncertainty visible for the clinician’s assessment.
It identifies a possible overlap to investigate. Establish whether the products were actually used together, their strengths, amounts and times before judging total exposure. A historical pack and a current strip do not by themselves show simultaneous use.
Updated on . This article combines the cited references with Bractis’s original workflow analysis and illustrative examples. Product capabilities depend on the configured scope. No independent clinical or legal review is claimed.
UK guidance supporting distinctions between reaction types and respiratory context. No drug challenge, alternative regimen or Indian legal rule is supplied.
General medicine–medicine and medicine–condition distinctions; not an NSAID selection protocol.
Official reporting entry point checked 28 October 2026, including professional and Indian-language patient forms. The page contains older programme material; no historical centre count, form version or reporting acknowledgement is treated as current evidence.
Record uncertain allergy histories with source-preserving examples, dated assessments and checks across prescribing, referral and export.
Reconcile kidney reports, check indexed eGFR conversions and prevent double BSA adjustment with worked examples for Indian clinic prescribing reviews.
Document suspected ADRs with a worked event timeline, linked PvPI follow-ups, the general IPC reporting form and separate clinical and reporting responsibilities.
Clarify a fictional allergy category while preserving a separate gastrointestinal history, uncertain respiratory event and combination-product evidence.
Request a clinic demo